<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39341153</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>11</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>14</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2352-3964</ISSN><JournalIssue CitedMedium="Internet"><Volume>108</Volume><PubDate><Year>2024</Year><Month>Oct</Month></PubDate></JournalIssue><Title>EBioMedicine</Title><ISOAbbreviation>EBioMedicine</ISOAbbreviation></Journal><ArticleTitle>Ultrapotent class I neutralizing antibodies post Omicron breakthrough infection overcome broad SARS-CoV-2 escape variants.</ArticleTitle><Pagination><StartPage>105354</StartPage><MedlinePgn>105354</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">105354</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ebiom.2024.105354</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2352-3964(24)00390-6</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The spread of emerging SARS-CoV-2 immune escape sublineages, especially JN.1 and KP.2, has resulted in new waves of COVID-19 globally. The evolving memory B cell responses elicited by the parental Omicron variants to subvariants with substantial antigenic drift remain incompletely investigated.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Using the single B cell antibody cloning technology, we isolated single memory B cells, delineated the B cell receptor repertoire and conducted the pseudovirus-based assay for recovered neutralizing antibodies (NAb) screening. We analyzed the cryo-EM structures of top broadly NAbs (bnAbs) and evaluated their in vivo efficacy (golden Syrian hamster model).</AbstractText><AbstractText Label="FINDINGS" NlmCategory="RESULTS">By investigating the evolution of human B cell immunity, we discovered a new panel of bnAbs arising from vaccinees after Omicron BA.2/BA.5 breakthrough infections. Two lead bnAbs neutralized major Omicron subvariants including JN.1 and KP.2 with IC<sub>50</sub> values less than 10 ng/mL, representing ultrapotent receptor binding domain (RBD)-specific class I bnAbs. They belonged to the IGHV3-53/3-66 clonotypes instead of evolving from the pre-existing vaccine-induced IGHV1-58/IGKV3-20 bnAb ZCB11. Despite sequence diversity, they targeted previously unrecognized, highly conserved conformational epitopes in the receptor binding motif (RBM) for ultrapotent ACE2 blockade. The lead bnAb ZCP3B4 not only protected the lungs of hamsters intranasally challenged with BA.5.2, BQ.1.1 and XBB.1.5 but also prevented their contact transmission.</AbstractText><AbstractText Label="INTERPRETATION" NlmCategory="CONCLUSIONS">Our findings demonstrated that class I bnAbs have evolved an ultrapotent mode of action protecting against highly transmissible and broad Omicron escape variants, and their epitopes are potential targets for novel bnAbs and vaccine development.</AbstractText><AbstractText Label="FUNDING" NlmCategory="BACKGROUND">A full list of funding bodies that contributed to this study can be found in the Acknowledgements section.</AbstractText><CopyrightInformation>Copyright © 2024 The Author(s). Published by Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Luo</LastName><ForeName>Mengxiao</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>AIDS Institute, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong SAR, People's Republic of China; Department of Microbiology, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong SAR, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Runhong</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>AIDS Institute, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong SAR, People's Republic of China; Department of Microbiology, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong SAR, People's Republic of China; Department of Clinical Microbiology and Infection Control, The University of Hong Kong-Shenzhen Hospital, Shenzhen, Guangdong, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tang</LastName><ForeName>Bingjie</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Division of Life Science, The Hong Kong University of Science and Technology, Clear Water Bay, Kowloon, Hong Kong SAR, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Hang</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Division of Life Science, The Hong Kong University of Science and Technology, Clear Water Bay, Kowloon, Hong Kong SAR, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Bohao</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>AIDS Institute, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong SAR, People's Republic of China; Department of Microbiology, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong SAR, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Na</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>AIDS Institute, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong SAR, People's Republic of China; Department of Microbiology, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong SAR, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mo</LastName><ForeName>Yufei</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>AIDS Institute, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong SAR, People's Republic of China; Department of Microbiology, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong SAR, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Pengfei</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>AIDS Institute, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong SAR, People's Republic of China; Department of Microbiology, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong SAR, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Ye Lim</ForeName><Initials>YL</Initials><AffiliationInfo><Affiliation>Centre for Virology, Vaccinology and Therapeutics, Health@InnoHK, The University of Hong Kong, Hong Kong SAR, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ip</LastName><ForeName>Jonathan Daniel</ForeName><Initials>JD</Initials><AffiliationInfo><Affiliation>Department of Microbiology, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong SAR, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wing-Ho Chu</LastName><ForeName>Allen</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Microbiology, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong SAR, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chan</LastName><ForeName>Wan-Mui</ForeName><Initials>WM</Initials><AffiliationInfo><Affiliation>Department of Microbiology, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong SAR, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Man</LastName><ForeName>Hiu-On</ForeName><Initials>HO</Initials><AffiliationInfo><Affiliation>AIDS Institute, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong SAR, People's Republic of China; Department of Microbiology, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong SAR, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Yuting</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>AIDS Institute, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong SAR, People's Republic of China; Department of Microbiology, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong SAR, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>To</LastName><ForeName>Kelvin Kai-Wang</ForeName><Initials>KK</Initials><AffiliationInfo><Affiliation>Department of Microbiology, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong SAR, People's Republic of China; Department of Clinical Microbiology and Infection Control, The University of Hong Kong-Shenzhen Hospital, Shenzhen, Guangdong, People's Republic of China; Centre for Virology, Vaccinology and Therapeutics, Health@InnoHK, The University of Hong Kong, Hong Kong SAR, People's Republic of China; State Key Laboratory of Emerging Infectious Diseases, The University of Hong Kong, Pokfulam, Hong Kong SAR, People's Republic of China; Department of Microbiology, Queen Mary Hospital, Pokfulam, Hong Kong SAR, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yuen</LastName><ForeName>Kwok-Yung</ForeName><Initials>KY</Initials><AffiliationInfo><Affiliation>Department of Microbiology, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong SAR, People's Republic of China; Department of Clinical Microbiology and Infection Control, The University of Hong Kong-Shenzhen Hospital, Shenzhen, Guangdong, People's Republic of China; Centre for Virology, Vaccinology and Therapeutics, Health@InnoHK, The University of Hong Kong, Hong Kong SAR, People's Republic of China; State Key Laboratory of Emerging Infectious Diseases, The University of Hong Kong, Pokfulam, Hong Kong SAR, People's Republic of China; Department of Microbiology, Queen Mary Hospital, Pokfulam, Hong Kong SAR, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dang</LastName><ForeName>Shangyu</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Division of Life Science, The Hong Kong University of Science and Technology, Clear Water Bay, Kowloon, Hong Kong SAR, People's Republic of China; HKUST-Shenzhen Research Institute, Nanshan, Shenzhen, 518057, People's Republic of China. Electronic address: sdang@ust.hk.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Zhiwei</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>AIDS Institute, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong SAR, People's Republic of China; Department of Microbiology, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong SAR, People's Republic of China; Department of Clinical Microbiology and Infection Control, The University of Hong Kong-Shenzhen Hospital, Shenzhen, Guangdong, People's Republic of China; Centre for Virology, Vaccinology and Therapeutics, Health@InnoHK, The University of Hong Kong, Hong Kong SAR, People's Republic of China; State Key Laboratory of Emerging Infectious Diseases, The University of Hong Kong, Pokfulam, Hong Kong SAR, People's Republic of China. Electronic address: zchenai@hku.hk.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>EBioMedicine</MedlineTA><NlmUniqueID>101647039</NlmUniqueID><ISSNLinking>2352-3964</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057134">Antibodies, Neutralizing</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D064370">Spike Glycoprotein, Coronavirus</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000086663">COVID-19 Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000657845">spike protein, SARS-CoV-2</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Organism" UI="C000711908">SARS-CoV-2 variants</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057134" MajorTopicYN="Y">Antibodies, Neutralizing</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="Y">Antibodies, Viral</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057131" MajorTopicYN="N">Immune Evasion</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006224" MajorTopicYN="N">Cricetinae</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D064370" MajorTopicYN="N">Spike Glycoprotein, Coronavirus</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086663" MajorTopicYN="N">COVID-19 Vaccines</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001402" MajorTopicYN="N">B-Lymphocytes</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000093742" MajorTopicYN="N">Breakthrough Infections</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Broadly neutralizing antibody</Keyword><Keyword MajorTopicYN="N">Omicron breakthrough infection</Keyword><Keyword MajorTopicYN="N">Prevention of XBB.1.5 transmission</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">Structural fitness of antibody</Keyword></KeywordList><CoiStatement>Declaration of interests The other authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>6</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>9</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>12</Day><Hour>13</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>29</Day><Hour>4</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>18</Hour><Minute>9</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>27</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39341153</ArticleId><ArticleId IdType="pmc">PMC11470419</ArticleId><ArticleId IdType="doi">10.1016/j.ebiom.2024.105354</ArticleId><ArticleId IdType="pii">S2352-3964(24)00390-6</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Zhou D., Zhou R., Chen Z. Human neutralizing antibodies for SARS-CoV-2 prevention and immunotherapy. Immunother Adv. 2022;2(1)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8755319</ArticleId><ArticleId IdType="pubmed">35915816</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou R., To K.K., Wong Y.C., et al. Acute SARS-CoV-2 infection impairs dendritic cell and T cell responses. Immunity. 2020;53(4):864–877.e5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7402670</ArticleId><ArticleId IdType="pubmed">32791036</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu L., To K.K., Chan K.H., et al. High neutralizing antibody titer in intensive care unit patients with COVID-19. Emerg Microb Infect. 2020;9(1):1664–1670.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7473321</ArticleId><ArticleId IdType="pubmed">32618497</ArticleId></ArticleIdList></Reference><Reference><Citation>Wajnberg A., Amanat F., Firpo A., et al. Robust neutralizing antibodies to SARS-CoV-2 infection persist for months. Science. 2020;370(6521):1227–1230.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7810037</ArticleId><ArticleId IdType="pubmed">33115920</ArticleId></ArticleIdList></Reference><Reference><Citation>Polack F.P., Thomas S.J., Kitchin N., et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383(27):2603–2615.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7745181</ArticleId><ArticleId IdType="pubmed">33301246</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Z., Schmidt F., Weisblum Y., et al. mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants. Nature. 2021;592(7855):616–622.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8503938</ArticleId><ArticleId IdType="pubmed">33567448</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou R., Liu N., Li X., et al. Three-dose vaccination-induced immune responses protect against SARS-CoV-2 Omicron BA.2: a population-based study in Hong Kong. Lancet Reg Health West Pac. 2023;32</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9786166</ArticleId><ArticleId IdType="pubmed">36591327</ArticleId></ArticleIdList></Reference><Reference><Citation>Agrawal U., Katikireddi S.V., McCowan C., et al. COVID-19 hospital admissions and deaths after BNT162b2 and ChAdOx1 nCoV-19 vaccinations in 2.57 million people in Scotland (EAVE II): a prospective cohort study. Lancet Respir Med. 2021;9(12):1439–1449.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8480963</ArticleId><ArticleId IdType="pubmed">34599903</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu L., Iketani S., Guo Y., et al. Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2. Nature. 2022;602(7898):676–681.</Citation><ArticleIdList><ArticleId IdType="pubmed">35016198</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang P., Nair M.S., Liu L., et al. Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7. Nature. 2021;593(7857):130–135.</Citation><ArticleIdList><ArticleId IdType="pubmed">33684923</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Q., Guo Y., Iketani S., et al. Antibody evasion by SARS-CoV-2 Omicron subvariants BA.2.12.1, BA.4 and BA.5. Nature. 2022;608(7923):603–608.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9385487</ArticleId><ArticleId IdType="pubmed">35790190</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Q., Iketani S., Li Z., et al. Alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants. Cell. 2023;186(2):279–286.e8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9747694</ArticleId><ArticleId IdType="pubmed">36580913</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou B., Zhou R., Tang B., et al. A broadly neutralizing antibody protects Syrian hamsters against SARS-CoV-2 Omicron challenge. Nat Commun. 2022;13(1):3589.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9223271</ArticleId><ArticleId IdType="pubmed">35739114</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y., Zhao X., Zhou H., Zhu H., Jiang S., Wang P. Broadly neutralizing antibodies to SARS-CoV-2 and other human coronaviruses. Nat Rev Immunol. 2023;23(3):189–199.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9514166</ArticleId><ArticleId IdType="pubmed">36168054</ArticleId></ArticleIdList></Reference><Reference><Citation>Andrews N., Stowe J., Kirsebom F., et al. Covid-19 vaccine effectiveness against the omicron (B.1.1.529) variant. N Engl J Med. 2022;386(16):1532–1546.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8908811</ArticleId><ArticleId IdType="pubmed">35249272</ArticleId></ArticleIdList></Reference><Reference><Citation>Lau J.J., Cheng S.M.S., Leung K., et al. Real-world COVID-19 vaccine effectiveness against the Omicron BA.2 variant in a SARS-CoV-2 infection-naive population. Nat Med. 2023;29(2):348–357.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9941049</ArticleId><ArticleId IdType="pubmed">36652990</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao Y., Wang J., Jian F., et al. Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies. Nature. 2022;602(7898):657–663.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8866119</ArticleId><ArticleId IdType="pubmed">35016194</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao Y., Yisimayi A., Jian F., et al. BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection. Nature. 2022;608(7923):593–602.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9385493</ArticleId><ArticleId IdType="pubmed">35714668</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Q., Iketani S., Li Z., et al. Antigenic characterization of the SARS-CoV-2 Omicron subvariant BA.2.75. Cell Host Microbe. 2022;30(11):1512–1517.e4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9444898</ArticleId><ArticleId IdType="pubmed">36108630</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao Y., Jian F., Wang J., et al. Imprinted SARS-CoV-2 humoral immunity induces convergent Omicron RBD evolution. Nature. 2023;614(7948):521–529.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9931576</ArticleId><ArticleId IdType="pubmed">36535326</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang L., Kempf A., Nehlmeier I., et al. Neutralisation sensitivity of SARS-CoV-2 lineages EG.5.1 and XBB.2.3. Lancet Infect Dis. 2023;23(10):e391–e392.</Citation><ArticleIdList><ArticleId IdType="pubmed">37716358</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Q., Guo Y., Liu L., et al. Antigenicity and receptor affinity of SARS-CoV-2 BA.2.86 spike. Nature. 2023;624(7992):639–644.</Citation><ArticleIdList><ArticleId IdType="pubmed">37871613</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaku Y., Uriu K., Kosugi Y., et al. Virological characteristics of the SARS-CoV-2 KP.2 variant. Lancet Infect Dis. 2024;24:e416.</Citation><ArticleIdList><ArticleId IdType="pubmed">38782005</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang X., Chen L.L., Ip J.D., et al. Omicron sublineage recombinant XBB evades neutralising antibodies in recipients of BNT162b2 or CoronaVac vaccines. Lancet Microbe. 2023;4(3)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9725777</ArticleId><ArticleId IdType="pubmed">36493789</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Q., Bowen A., Tam A.R., et al. SARS-CoV-2 neutralising antibodies after bivalent versus monovalent booster. Lancet Infect Dis. 2023;23(5):527–528.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10058662</ArticleId><ArticleId IdType="pubmed">37003292</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Q., Bowen A., Valdez R., et al. Antibody response to omicron BA.4-BA.5 bivalent booster. N Engl J Med. 2023;388(6):567–569.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9847504</ArticleId><ArticleId IdType="pubmed">36630643</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang S., Yu Y., Xu Y., et al. Fast evolution of SARS-CoV-2 BA.2.86 to JN.1 under heavy immune pressure. Lancet Infect Dis. 2024;24(2):e70–e72.</Citation><ArticleIdList><ArticleId IdType="pubmed">38109919</ArticleId></ArticleIdList></Reference><Reference><Citation>Barnes C.O., Jette C.A., Abernathy M.E., et al. SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies. Nature. 2020;588(7839):682–687.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8092461</ArticleId><ArticleId IdType="pubmed">33045718</ArticleId></ArticleIdList></Reference><Reference><Citation>Hastie K.M., Li H., Bedinger D., et al. Defining variant-resistant epitopes targeted by SARS-CoV-2 antibodies: a global consortium study. Science. 2021;374(6566):472–478.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9302186</ArticleId><ArticleId IdType="pubmed">34554826</ArticleId></ArticleIdList></Reference><Reference><Citation>Qi H., Liu B., Wang X., Zhang L. The humoral response and antibodies against SARS-CoV-2 infection. Nat Immunol. 2022;23(7):1008–1020.</Citation><ArticleIdList><ArticleId IdType="pubmed">35761083</ArticleId></ArticleIdList></Reference><Reference><Citation>Jian F., Feng L., Yang S., et al. Convergent evolution of SARS-CoV-2 XBB lineages on receptor-binding domain 455-456 synergistically enhances antibody evasion and ACE2 binding. PLoS Pathog. 2023;19(12)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10766189</ArticleId><ArticleId IdType="pubmed">38117863</ArticleId></ArticleIdList></Reference><Reference><Citation>Schaefer-Babajew D., Wang Z., Muecksch F., et al. Antibody feedback regulates immune memory after SARS-CoV-2 mRNA vaccination. Nature. 2023;613(7945):735–742.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9876794</ArticleId><ArticleId IdType="pubmed">36473496</ArticleId></ArticleIdList></Reference><Reference><Citation>Tong P., Gautam A., Windsor I.W., et al. Memory B cell repertoire for recognition of evolving SARS-CoV-2 spike. Cell. 2021;184(19):4969–4980.e15.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8299219</ArticleId><ArticleId IdType="pubmed">34332650</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan J.F., Yip C.C., To K.K., et al. Improved molecular diagnosis of COVID-19 by the novel, highly sensitive and specific COVID-19-RdRp/hel real-time reverse transcription-PCR assay validated in vitro and with clinical specimens. J Clin Microbiol. 2020;58(5) e00310–e20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7180250</ArticleId><ArticleId IdType="pubmed">32132196</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo M., Zhou B., Reddem E.R., et al. Structural insights into broadly neutralizing antibodies elicited by hybrid immunity against SARS-CoV-2. Emerg Microb Infect. 2023;12(1)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9817130</ArticleId><ArticleId IdType="pubmed">36354024</ArticleId></ArticleIdList></Reference><Reference><Citation>Punjani A., Rubinstein J.L., Fleet D.J., Brubaker M.A. cryoSPARC: algorithms for rapid unsupervised cryo-EM structure determination. Nat Methods. 2017;14(3):290–296.</Citation><ArticleIdList><ArticleId IdType="pubmed">28165473</ArticleId></ArticleIdList></Reference><Reference><Citation>Zivanov J., Oton J., Ke Z., et al. A Bayesian approach to single-particle electron cryo-tomography in RELION-4.0. Elife. 2022;11</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9815803</ArticleId><ArticleId IdType="pubmed">36468689</ArticleId></ArticleIdList></Reference><Reference><Citation>Geng Q., Shi K., Ye G., Zhang W., Aihara H., Li F. Structural basis for human receptor recognition by SARS-CoV-2 omicron variant BA.1. J Virol. 2022;96(8)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9044962</ArticleId><ArticleId IdType="pubmed">35343765</ArticleId></ArticleIdList></Reference><Reference><Citation>Jumper J., Evans R., Pritzel A., et al. Highly accurate protein structure prediction with AlphaFold. Nature. 2021;596(7873):583–589.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8371605</ArticleId><ArticleId IdType="pubmed">34265844</ArticleId></ArticleIdList></Reference><Reference><Citation>Emsley P., Cowtan K. Coot: model-building tools for molecular graphics. Acta Crystallogr D Biol Crystallogr. 2004;60(Pt 12 Pt 1):2126–2132.</Citation><ArticleIdList><ArticleId IdType="pubmed">15572765</ArticleId></ArticleIdList></Reference><Reference><Citation>Adams P.D., Gopal K., Grosse-Kunstleve R.W., et al. Recent developments in the PHENIX software for automated crystallographic structure determination. J Synchrotron Radiat. 2004;11(Pt 1):53–55.</Citation><ArticleIdList><ArticleId IdType="pubmed">14646133</ArticleId></ArticleIdList></Reference><Reference><Citation>Pettersen E.F., Goddard T.D., Huang C.C., et al. UCSF Chimera--a visualization system for exploratory research and analysis. J Comput Chem. 2004;25(13):1605–1612.</Citation><ArticleIdList><ArticleId IdType="pubmed">15264254</ArticleId></ArticleIdList></Reference><Reference><Citation>Pettersen E.F., Goddard T.D., Huang C.C., et al. UCSF ChimeraX: structure visualization for researchers, educators, and developers. Protein Sci. 2021;30(1):70–82.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7737788</ArticleId><ArticleId IdType="pubmed">32881101</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan J.F., Zhang A.J., Yuan S., et al. Simulation of the clinical and pathological manifestations of coronavirus disease 2019 (COVID-19) in a golden Syrian hamster model: implications for disease pathogenesis and transmissibility. Clin Infect Dis. 2020;71(9):2428–2446.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7184405</ArticleId><ArticleId IdType="pubmed">32215622</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan S., Ye Z.W., Liang R., et al. Pathogenicity, transmissibility, and fitness of SARS-CoV-2 Omicron in Syrian hamsters. Science. 2022;377(6604):428–433.</Citation><ArticleIdList><ArticleId IdType="pubmed">35737809</ArticleId></ArticleIdList></Reference><Reference><Citation>Tortorici M.A., Beltramello M., Lempp F.A., et al. Ultrapotent human antibodies protect against SARS-CoV-2 challenge via multiple mechanisms. Science. 2020;370(6519):950–957.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7857395</ArticleId><ArticleId IdType="pubmed">32972994</ArticleId></ArticleIdList></Reference><Reference><Citation>Jones B.E., Brown-Augsburger P.L., Corbett K.S., et al. The neutralizing antibody, LY-CoV555, protects against SARS-CoV-2 infection in nonhuman primates. Sci Transl Med. 2021;13(593):eabf1906.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8284311</ArticleId><ArticleId IdType="pubmed">33820835</ArticleId></ArticleIdList></Reference><Reference><Citation>Westendorf K., Zentelis S., Wang L., et al. LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants. Cell Rep. 2022;39(7)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9035363</ArticleId><ArticleId IdType="pubmed">35568025</ArticleId></ArticleIdList></Reference><Reference><Citation>Tortorici M.A., Czudnochowski N., Starr T.N., et al. Broad sarbecovirus neutralization by a human monoclonal antibody. Nature. 2021;597(7874):103–108.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9341430</ArticleId><ArticleId IdType="pubmed">34280951</ArticleId></ArticleIdList></Reference><Reference><Citation>Quandt J., Muik A., Salisch N., et al. Omicron BA.1 breakthrough infection drives cross-variant neutralization and memory B cell formation against conserved epitopes. Sci Immunol. 2022;7(75)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9162083</ArticleId><ArticleId IdType="pubmed">35653438</ArticleId></ArticleIdList></Reference><Reference><Citation>Park Y.J., Pinto D., Walls A.C., et al. Imprinted antibody responses against SARS-CoV-2 Omicron sublineages. Science. 2022;378(6620):619–627.</Citation><ArticleIdList><ArticleId IdType="pubmed">36264829</ArticleId></ArticleIdList></Reference><Reference><Citation>Alsoussi W.B., Malladi S.K., Zhou J.Q., et al. SARS-CoV-2 Omicron boosting induces de novo B cell response in humans. Nature. 2023;617(7961):592–598.</Citation><ArticleIdList><ArticleId IdType="pubmed">37011668</ArticleId></ArticleIdList></Reference><Reference><Citation>Sokal A., Barba-Spaeth G., Hunault L., et al. SARS-CoV-2 Omicron BA.1 breakthrough infection drives late remodeling of the memory B cell repertoire in vaccinated individuals. Immunity. 2023;56(9):2137–21351.e7.</Citation><ArticleIdList><ArticleId IdType="pubmed">37543032</ArticleId></ArticleIdList></Reference><Reference><Citation>Ju B., Zhang Q., Wang Z., et al. Infection with wild-type SARS-CoV-2 elicits broadly neutralizing and protective antibodies against omicron subvariants. Nat Immunol. 2023;24(4):690–699.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10063446</ArticleId><ArticleId IdType="pubmed">36914890</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan M., Liu H., Wu N.C., et al. Structural basis of a shared antibody response to SARS-CoV-2. Science. 2020;369(6507):1119–1123.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7402627</ArticleId><ArticleId IdType="pubmed">32661058</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Q., Ju B., Ge J., et al. Potent and protective IGHV3-53/3-66 public antibodies and their shared escape mutant on the spike of SARS-CoV-2. Nat Commun. 2021;12(1):4210.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8270942</ArticleId><ArticleId IdType="pubmed">34244522</ArticleId></ArticleIdList></Reference><Reference><Citation>Raybould M.I.J., Kovaltsuk A., Marks C., Deane C.M. CoV-AbDab: the coronavirus antibody database. Bioinformatics. 2021;37(5):734–735.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7558925</ArticleId><ArticleId IdType="pubmed">32805021</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y., Yuan M., Lv H., Peng J., Wilson I.A., Wu N.C. A large-scale systematic survey reveals recurring molecular features of public antibody responses to SARS-CoV-2. Immunity. 2022;55(6):1105–11017.e4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8947961</ArticleId><ArticleId IdType="pubmed">35397794</ArticleId></ArticleIdList></Reference><Reference><Citation>Setliff I., McDonnell W.J., Raju N., et al. Multi-donor Longitudinal antibody repertoire sequencing reveals the existence of public antibody clonotypes in HIV-1 infection. Cell Host Microbe. 2018;23(6):845–854.e6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6002606</ArticleId><ArticleId IdType="pubmed">29861170</ArticleId></ArticleIdList></Reference><Reference><Citation>Li L., Chen X., Wang Z., et al. Breakthrough infection elicits hypermutated IGHV3-53/3-66 public antibodies with broad and potent neutralizing activity against SARS-CoV-2 variants including the emerging EG.5 lineages. PLoS Pathog. 2023;19(12)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10721163</ArticleId><ArticleId IdType="pubmed">38048356</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaku C.I., Starr T.N., Zhou P., et al. Evolution of antibody immunity following Omicron BA.1 breakthrough infection. Nat Commun. 2023;14(1):2751.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10180619</ArticleId><ArticleId IdType="pubmed">37173311</ArticleId></ArticleIdList></Reference><Reference><Citation>Starr T.N., Greaney A.J., Hilton S.K., et al. Deep mutational Scanning of SARS-CoV-2 receptor binding domain reveals Constraints on folding and ACE2 binding. Cell. 2020;182(5):1295–1310.e20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7418704</ArticleId><ArticleId IdType="pubmed">32841599</ArticleId></ArticleIdList></Reference><Reference><Citation>Changrob S., Halfmann P.J., Liu H., et al. Site of vulnerability on SARS-CoV-2 spike induces broadly protective antibody against antigenically distinct Omicron subvariants. J Clin Invest. 2023;133(8)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10104900</ArticleId><ArticleId IdType="pubmed">36862518</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang R., Zhang Q., Ge J., et al. Analysis of SARS-CoV-2 variant mutations reveals neutralization escape mechanisms and the ability to use ACE2 receptors from additional species. Immunity. 2021;54(7):1611–16121.e5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8185182</ArticleId><ArticleId IdType="pubmed">34166623</ArticleId></ArticleIdList></Reference><Reference><Citation>Shuai H., Chan J.F., Hu B., et al. The viral fitness and intrinsic pathogenicity of dominant SARS-CoV-2 Omicron sublineages BA.1, BA.2, and BA.5. eBioMedicine. 2023;95</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10448076</ArticleId><ArticleId IdType="pubmed">37579626</ArticleId></ArticleIdList></Reference><Reference><Citation>Khan K., Karim F., Ganga Y., et al. Author Correction: omicron BA.4/BA.5 escape neutralizing immunity elicited by BA.1 infection. Nat Commun. 2022;13(1):6057.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9559132</ArticleId><ArticleId IdType="pubmed">36229444</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou T., Wang L., Misasi J., et al. Structural basis for potent antibody neutralization of SARS-CoV-2 variants including B.1.1.529. Science. 2022;376(6591)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9580340</ArticleId><ArticleId IdType="pubmed">35324257</ArticleId></ArticleIdList></Reference><Reference><Citation>Tuekprakhon A., Nutalai R., Dijokaite-Guraliuc A., et al. Antibody escape of SARS-CoV-2 Omicron BA.4 and BA.5 from vaccine and BA.1 serum. Cell. 2022;185(14):2422–2433.e13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9181312</ArticleId><ArticleId IdType="pubmed">35772405</ArticleId></ArticleIdList></Reference><Reference><Citation>Henderson R., Edwards R.J., Mansouri K., et al. Controlling the SARS-CoV-2 spike glycoprotein conformation. Nat Struct Mol Biol. 2020;27(10):925–933.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8581954</ArticleId><ArticleId IdType="pubmed">32699321</ArticleId></ArticleIdList></Reference><Reference><Citation>Lan J., Ge J., Yu J., et al. Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. Nature. 2020;581(7807):215–220.</Citation><ArticleIdList><ArticleId IdType="pubmed">32225176</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou D., Chan J.F., Zhou B., et al. Robust SARS-CoV-2 infection in nasal turbinates after treatment with systemic neutralizing antibodies. Cell Host Microbe. 2021;29(4):551–563.e5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7904446</ArticleId><ArticleId IdType="pubmed">33657424</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou B., Zhou R., Chan J.F., et al. SARS-CoV-2 hijacks neutralizing dimeric IgA for nasal infection and injury in Syrian hamsters. Emerg Microb Infect. 2023;12(2):2245921.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10444022</ArticleId><ArticleId IdType="pubmed">37542391</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>